Skip to content

Study · Animal study (in vivo) · mouse · 2014

16 results

Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.

McClean PL, Hölscher C

Neuropharmacology8 Aug 2014Cited by 150 (Europe PMC)

PMID25107586 (opens in a new tab)DOI10.1016/j.neuropharm.2014.07.015 (opens in a new tab)PepBankPUB-25107586
Publisher pagePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, ten weeks of liraglutide at 2.5 or 25 nmol/kg improved object recognition performance versus saline.

    In plain wordsIn mice with Alzheimer's-like disease, liraglutide improved performance in an object recognition memory task compared with saline.

    Peptide
    Liraglutide
    Outcome
    IncreaseObject recognition performance
    Study

    mousen: not reported in source

    APPswe/PS1ΔE9 mouse model of Alzheimer's disease
    Comparator
    Saline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    2.5 or 25 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In APP/PS1 mice, liraglutide strongly increased hippocampal long-term potentiation, a measure of synaptic plasticity.

    In plain wordsIn mice with Alzheimer's-like disease, liraglutide strongly increased a measure of brain synaptic plasticity.

    Peptide
    Liraglutide
    Outcome
    IncreaseHippocampal long-term potentiation
    Study

    mousen: not reported in source

    APPswe/PS1ΔE9 mouse model of Alzheimer's disease
    Comparator
    Saline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    2.5 or 25 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    When analysing synaptic plasticity in the hippocampus, LTP was strongly increased in APP/PS1 mice by either drug.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In APP/PS1 mice, liraglutide prevented the reduction of synapse numbers seen in untreated APP/PS1 mice.

    In plain wordsIn mice with Alzheimer's-like disease, liraglutide prevented the loss of synapses seen in untreated mice.

    Peptide
    Liraglutide
    Outcome
    IncreaseSynapse numbers
    Study

    mousen: not reported in source

    APPswe/PS1ΔE9 mouse model of Alzheimer's disease
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 or 25 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The reduction of synapse numbers seen in APP/PS1 mice was prevented by the drugs.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, liraglutide at all doses reduced amyloid plaque load and dense-core Congo red positive plaque load in the cortex.

    In plain wordsIn mice with Alzheimer's-like disease, liraglutide at all doses reduced amyloid plaque in the brain cortex.

    Peptide
    Liraglutide
    Outcome
    DecreaseCortical amyloid plaque load
    Study

    mousen: not reported in source

    APPswe/PS1ΔE9 mouse model of Alzheimer's disease
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    2.5 or 25 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The amyloid plaque load and dense-core Congo red positive plaque load in the cortex was reduced by both drugs at all doses.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In APP/PS1 mice, liraglutide reduced the chronic inflammation response, measured as microglial activation.

    In plain wordsIn mice with Alzheimer's-like disease, liraglutide reduced brain inflammation seen as microglial activation.

    Peptide
    Liraglutide
    Outcome
    DecreaseMicroglial activation (chronic inflammation)
    Study

    mousen: not reported in source

    APPswe/PS1ΔE9 mouse model of Alzheimer's disease
    Comparator
    Saline
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    2.5 or 25 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The chronic inflammation response (microglial activation) was also reduced by all treatments.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide 1 nmol/kg improved object recognition compared with saline.

    In plain wordsIn mice with an Alzheimer's disease model, low-dose lixisenatide improved object recognition compared with saline.

    Peptide
    Lixisenatide
    Outcome
    IncreaseObject recognition
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Saline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    1 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide 10 nmol/kg improved object recognition compared with saline.

    In plain wordsIn mice with an Alzheimer's disease model, high-dose lixisenatide improved object recognition compared with saline.

    Peptide
    Lixisenatide
    Outcome
    IncreaseObject recognition
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Saline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    10 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide strongly increased hippocampal long-term potentiation compared with saline; separate dose estimates were not stated.

    In plain wordsIn mice with an Alzheimer's disease model, lixisenatide increased hippocampal synaptic plasticity compared with saline.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHippocampal long-term potentiation
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 or 10 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    When analysing synaptic plasticity in the hippocampus, LTP was strongly increased in APP/PS1 mice by either drug.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide 1 nmol/kg was the most effective tested regimen for hippocampal long-term potentiation.

    In plain wordsIn mice with an Alzheimer's disease model, low-dose lixisenatide produced the largest synaptic plasticity effect among tested regimens.

    Peptide
    Lixisenatide
    Outcome
    IncreaseRelative hippocampal long-term potentiation efficacy
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Other tested drug-dose regimens
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    Lixisenatide (1 nmol/kg) was most effective.
    2 context sentences
    Summary · context
    When analysing synaptic plasticity in the hippocampus, LTP was strongly increased in APP/PS1 mice by either drug.
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide prevented synapse loss compared with saline; separate dose estimates were not stated.

    In plain wordsIn mice with an Alzheimer's disease model, lixisenatide prevented synapse loss compared with saline.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSynapse numbers
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 or 10 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    The reduction of synapse numbers seen in APP/PS1 mice was prevented by the drugs.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide 1 nmol/kg reduced cortical amyloid plaque load compared with saline.

    In plain wordsIn mice with an Alzheimer's disease model, low-dose lixisenatide reduced cortical amyloid plaque load compared with saline.

    Peptide
    Lixisenatide
    Outcome
    DecreaseCortical amyloid plaque load
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    The amyloid plaque load and dense-core Congo red positive plaque load in the cortex was reduced by both drugs at all doses.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide 10 nmol/kg reduced cortical amyloid plaque load compared with saline.

    In plain wordsIn mice with an Alzheimer's disease model, high-dose lixisenatide reduced cortical amyloid plaque load compared with saline.

    Peptide
    Lixisenatide
    Outcome
    DecreaseCortical amyloid plaque load
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    The amyloid plaque load and dense-core Congo red positive plaque load in the cortex was reduced by both drugs at all doses.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide 1 nmol/kg reduced cortical dense-core Congo red positive plaque load compared with saline.

    In plain wordsIn mice with an Alzheimer's disease model, low-dose lixisenatide reduced dense-core cortical plaques compared with saline.

    Peptide
    Lixisenatide
    Outcome
    DecreaseDense-core Congo red positive plaque load
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    1 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    The amyloid plaque load and dense-core Congo red positive plaque load in the cortex was reduced by both drugs at all doses.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide 10 nmol/kg reduced cortical dense-core Congo red positive plaque load compared with saline.

    In plain wordsIn mice with an Alzheimer's disease model, high-dose lixisenatide reduced dense-core cortical plaques compared with saline.

    Peptide
    Lixisenatide
    Outcome
    DecreaseDense-core Congo red positive plaque load
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Saline
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    The amyloid plaque load and dense-core Congo red positive plaque load in the cortex was reduced by both drugs at all doses.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide 1 nmol/kg reduced microglial activation compared with saline.

    In plain wordsIn mice with an Alzheimer's disease model, low-dose lixisenatide reduced microglial activation compared with saline.

    Peptide
    Lixisenatide
    Outcome
    DecreaseMicroglial activation
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Saline
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    1 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    The chronic inflammation response (microglial activation) was also reduced by all treatments.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, lixisenatide 10 nmol/kg reduced microglial activation compared with saline.

    In plain wordsIn mice with an Alzheimer's disease model, high-dose lixisenatide reduced microglial activation compared with saline.

    Peptide
    Lixisenatide
    Outcome
    DecreaseMicroglial activation
    Study

    mousen: not reported in source

    APP/PS1 Alzheimer's disease mice
    Comparator
    Saline
    Outcome group
    Inflammation markers · Nervous system and cognition
    Studied dose
    10 nmol/kg daily · intraperitoneal · ten weeksAs given in this study (mouse).

    Source sentences

    Summary
    The chronic inflammation response (microglial activation) was also reduced by all treatments.
    1 context sentence
    Summary · context
    After ten weeks of daily i.p. injections with liraglutide (2.5 or 25 nmol/kg) or lixisenatide (1 or 10 nmol/kg) or saline of APP/PS1 mice at an age when amyloid plaques had already formed, performance in an object recognition task was improved in APP/PS1 mice by both drugs at all doses tested.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 3

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.